Clinical trial
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With…
NCT00304252 · EMD Serono, Industry · Terminated
Key facts
| NCT number | NCT00304252 |
|---|---|
| Title | Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease |
| Official title | A Phase II, Multicenter, Randomised, Double-blind, Placebo Controlled, Dose Finding Study of Subcutaneously Administered Interferon Beta-1a for Maintenance of Remission in Patients With Crohn's Disease |
| Lead sponsor | EMD Serono, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | Interferon beta-1a |
| Enrollment | 192 |
| Start date | Nov 1, 2001 |
| Completion | Sep 1, 2003 |
| First posted | Mar 17, 2006 |
| Last update posted | Aug 6, 2013 |
| Countries | Germany, Italy, Sweden, Switzerland, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: